Placental growth factor: What hematologists need to know.
Although first identified in placenta, the angiogenic factor known as placental growth factor (PlGF) can be widely expressed in ischemic or damaged tissues. Recent studies have indicated that PlGF is a relevant factor in the pathobiology of blood diseases including hemoglobinopathies and hematologic malignancies. Therapies for such blood diseases may one day be based upon these and ongoing investigations into the role of PlGF in sickle cell disease, acute and chronic leukemias, and complications related to hematopoietic cell transplantation. In this review, we summarize recent studies regarding the potential role of PlGF in blood disorders and suggest avenues for future research.
Oregon Health and Science University, Center for Hematologic Malignancies, Portland, OR, USA. Electronic address: newelll@ohsu.edu.
Laura F
LF
Newell
University of Minnesota, Blood and Marrow Transplant Program, Minneapolis, MN, USA. Electronic address: sgholtan@umn.edu.
Shernan G
SG
Holtan
D000818:Animals; D015415:Biomarkers; D005786:Gene Expression Regulation; D006402:Hematologic Diseases / Q000209:etiology / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000209:etiology / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D000072483:Placenta Growth Factor / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D011485:Protein Binding; D015398:Signal Transduction; D014184:Transplantation, Homologous
D015415:Biomarkers; D000072483:Placenta Growth Factor
Graft-versus-host disease; Hematopoietic cell transplantation; Leukemia; Placental growth factor; Sickle cell anemia